{
  "docId": "019de076-e0bc-7319-b2fa-5eeb46bcf895",
  "docSlug": "439c1d555948cf75a9b0a41f96565740",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 29 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 29,
  "prevPage": 28,
  "nextPage": null,
  "slideType": "thesis_headline",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a split-layout: left side for financial summary, right side for milestones and value proposition.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-e0bc-7319-b2fa-5eeb46bcf895/29",
  "deckHref": "/decks/019de076-e0bc-7319-b2fa-5eeb46bcf895",
  "deckJsonHref": "/decks/019de076-e0bc-7319-b2fa-5eeb46bcf895.json",
  "deckAnchorHref": "/decks/019de076-e0bc-7319-b2fa-5eeb46bcf895#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.37,
        "y": 0.6
      },
      "kind": "framework",
      "text": "Solid Value \"Foundation\" MAT2203: Clinically Validated, Phase 3-ready asset, Highest unmet need",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86102920-9ec4-419d-ae68-9d3ceb90de7d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.13,
        "y": 0.38
      },
      "kind": "list",
      "text": "Runway into Q3 2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7da40837-3149-4aaf-b7fc-483195ac15fe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.13,
        "y": 0.75
      },
      "kind": "list",
      "text": "Non-Dilutive Financing Options",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b0eef048-6e91-45ff-950e-de6e43a31311",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.37,
        "y": 0.15
      },
      "kind": "list",
      "text": "Q1 - Successful Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis (the “ORALTO” Trial)",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e5bf67f-87fc-4716-ab44-519c712ee07c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.13,
        "y": 0.55
      },
      "kind": "metric",
      "text": "$18.2M",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f90f484-69fc-4cec-8e9a-d840c485e558",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.37,
        "y": 0.05
      },
      "kind": "title",
      "text": "Near-Term Milestones – Setup for Strong Start to 2024",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ba6b9ab-087c-4885-a261-7c897594f8e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.3,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Matinas Investment Thesis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "500c532a-8959-4580-a377-ccdfbc80f9d1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "value-proposition",
      "slug": null,
      "matchId": "36356f05-1a58-4bbf-8a9b-eeea9dc9693f",
      "evidence": "Solid Value Foundation section detailing asset benefits",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}